Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study - Merck & Co ( NYSE:MRK )
Tuesday, Merck & Co Inc MRK released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer ( NSCLC ) who received prior EGFR tyrosine kinase inhibitor ( TKI ) treatment.
| Ticker |
Sentiment |
Impact |
|
AKESF
|
Neutral
|
11 %
|
|
SKXJF
|
Somewhat Bullish
|
22 %
|
|
DSKYF
|
Somewhat Bullish
|
22 %
|
|
SMMT
|
Neutral
|
22 %
|
